CD47 and neoplasm: Moreover, in other cancer types, anti-CD47 blockade has been demonstrated to enhance macrophage ADCP of tumour cells in response to TAA-targeting IgG mAbs, including Trastuzumab, anti-CD20 IgG1 Rituximab (Rituxan), and anti-epidermal growth factor receptor (EGFR) IgG1 Cetuximab (Erbitux) [106].